VIsual and Anatomic Outcomes in nAMD Patients With Subretinal Hemorrhage After Treatment With Faricimab in the TRUCKEE Study

Authors

Hannah Khan
Aamir A. Aziz
Ashkan Abbey
David RP Almeida
Robert L. Avery
Himanshu K. Banda
Mark Barakat
Ramaneth Bhandari
Emmanuel Y. Chang
Sara Haug
Nikolas JS London
Veerak Sheth
Jeremy Wolfe, Beaumont Health
Michael A. Singer
Carl J. Danzig
Arshad M. Khanani

Document Type

Conference Proceeding

Publication Date

6-2023

Publication Title

Investigative Ophthalmology and Visual Science

Abstract

Purpose : Faricimab was recently approved by the FDA for neovascular age-related macular degeneration (nAMD). This multi-center, prospective study evaluates visual and anatomical improvements in nAMD patients with subretinal hemorrhages (SRH) following dual VEGF-A and Ang-2 inhibition with faricimab.

Methods : This multi-center, prospective study investigates nAMD patients with SRH following treatment with faricimab. Data collected includes demographics, treatment history, best corrected visual acuity (BCVA), central subfield thickness (CST), presence of SRH, presence and height of pigment epithelial detachment (PED), presence of subretinal/intraretinal fluid (SRF/IRF), and intraocular pressure (IOP). Snellen visual acuity was converted to Early Treatment Diabetic Retinopathy Study (ETDRS) scoring. SRH resolution and retinal fluid improvements are evaluated as a proportion of patients. Improvements in visual acuity, CST, and PED height are evaluated as averages. Safety is summarized.

Results : 17 eyes across 17 patients were recorded. The average age of 83.1 years and 70.5% of patients were female. Following one faricimab injection, 16 eyes saw a +3.45 letter (p=0.03034) mean increase, a -117.63mm (p=0.00118) mean decrease in CST, and resolution rates for SRH, SRF, and IRF of 11.8%, 60%, and 50%, respectively. Following three faricimab injections, 14 eyes demonstrated a +6.35 letter (p=0.13125) mean increase, mean CST decrease of -201.65mm (p=0.00298) and resolution rates for SRH, SRF, and IRF of 28.6%, 87.5%, and 66.7%, respectively. No adverse events have been reported.

Conclusions : NAMD patients with SRH have demonstrated favorable visual and anatomic outcomes following dual-inhibition treatment with faricimab, with acceptable safety compared to current agents. This study will continue to investigate safety and efficacy of faricimab in real-world nAMD patients with SRH. Latest data will be available at the time of presentation.

Volume

64

Issue

8

First Page

2187

Comments

Annual Meeting Association for Research in Vision and Ophthalmology, ARVO 2023, April 23-27, 2023, New Orleans, LA

Recommended Citation

Khan H, Aziz AA, Abbey AM, Almeida DRP, Avery RL, Banda HK, et al. [Wolfe J]. Visual and anatomic outcomes in nAMD paients with subretinal hemorrhage after treatment with faricimab in the TRUCKEE study. Invest Ophthal Vis Sci. 2023 Jun;64(8):2187.